A study we referenced earlier (Martin et al, 2022) included a treatment arm with 2-dose regimen of GAD65 Alum in combination with twice-daily oral GABA in 25 recent-onset T1D pediatric patients. Here, GAD2 is linked to type 1 diabetes mellitus.